iRadimed Corp (IRMD) Stock Down 3.8% but Still Overvalued -- GF Score: 92/100
On September 04, 2026, iRadimed Corp (IRMD) shares fell 3.8%, currently trading at $83.45. The stock has seen a notable decline, with a 52-week high of $107.90
IRMD - IRadimed Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$100.00
DETAILS
HIGH:
$120.00
LOW:
$60.00
MEDIAN:
$120.00
CONSENSUS:
$100.00
UPSIDE:
20.08%
Stock News
Algert Global LLC Sells 15,062 Shares of iRadimed Corporation $IRMD
Algert Global LLC trimmed its stake in iRadimed Corporation (NASDAQ: IRMD) by 17.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,994 shares of the medical equipment provider's stock after selling 15,062 shares during the period. Algert Global
iRadimed Corporation (NASDAQ:IRMD) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of iRadimed Corporation (NASDAQ: IRMD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong
iRadimed Q2 Earnings Call Highlights
iRadimed NASDAQ: IRMD reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp.
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025. Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026.
IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026
ORLANDO, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 second quarter financial results before the market opens on Friday, July 31, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It
This medical device maker, known for MRI-compatible equipment, reported a notable insider sale amid strong one-year stock performance.
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will attend the Goldman Sachs 47th Annual Global Healthcare Conference, to be held June 8–10, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida.
Why Iradimed Stock Topped the Market Today
Yet again, it posted growth and robust profitability in its latest quarter.
iRadimed Corp (IRMD) Shares Surge 4.4% -- What GF Score of 95 Tells Investors
On May 01, 2026, iRadimed Corp (IRMD) shares rose 4.4%, bringing the current price to $87.15. This movement comes amid a 52-week range that has seen a high of $
IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript
iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.
IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025. Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.
IRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026
ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
IRADIMED CORPORATION to Participate at the 25th Annual Needham Virtual Healthcare Conference
ORLANDO, Fla., April 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 25th Annual Needham Virtual Healthcare Conference.
Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock
iRadimed Corporation (NASDAQ: IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of iRadimed stock in a transaction on Monday, April 6th. The shares were sold at an average price of $96.02, for a total transaction of $480,100.00. Following the sale, the chief executive officer directly owned 2,220,000 shares of the company's stock, valued
Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock
iRadimed Corporation (NASDAQ: IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $100.38, for a total value of $501,900.00. Following the completion of the transaction, the chief executive officer directly owned 2,235,000 shares
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes
GMED, TCMD and IRMD tap GenAI to boost diagnostics and workflows, but high costs, regulation gaps and macro pressures still weigh on MedTech growth.
IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38 th Annual Roth Conference.
Price Targets
iRadimed price target raised to $120 from $100 at Lake Street
$120.00
(was $106.02)
Lake Street
iRadimed price target raised to $120 from $98 at Roth Capital
$120.00
(was $105.15)
Roth Capital
iRadimed price target raised to $98 from $90 at Roth Capital
$98.00
(was $84.11)
Kyle Bauser
·
Roth Capital
iRadimed price target raised to $100 from $75 at Lake Street
$100.00
(was $84.11)
Lake Street
iRadimed resumed with a Buy at Roth Capital
$90.00
(was $76.42)
Kyle Bauser
·
Roth Capital
iRadimed price target lowered to $60 from $65 at Roth MKM
$60.00
(was $46.15)
Jason Wittes
·
Roth Capital
Lake Street Capital Markets Reiterates Buy Rating on IRadimed Corp (IRMD)
$60.00
(was $43.28)
Frank Takkinen
·
Loop Capital Markets